key: cord-0971549-tfev3acf
authors: Kandetu, Theo-Ben; Dziuban, Eric J.; Sikuvi, Kaveto; Beard, Rachel S.; Nghihepa, Reginald; van Rooyen, Gerhard; Shiningavamwe, Andreas; Katjitae, Ismael
title: Persistence of Positive RT-PCR Results for Over 70 Days in Two Travelers with COVID-19
date: 2020-11-19
journal: Disaster medicine and public health preparedness
DOI: 10.1017/dmp.2020.450
sha: 01d1307c367824a69e5d2f509d7302933b3c3c2a
doc_id: 971549
cord_uid: tfev3acf

The relation of continuing to test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by reverse transcription real-time polymerase chain reaction (RT-PCR) to infectivity remains unclear, with numerous consequences. This report describes 2 patients with persistent viral detection by RT-PCR for 77 and 72 days, respectively, longer than other reported case-patients who were otherwise healthy.

The significance of continuing to test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by reverse transcription real-time polymerase chain reaction (RT-PCR) and its relation to infectivity for SARS-CoV-2 remain unclear. Some studies have linked symptomatic disease, male sex, age greater than 60 years, and severe forms of the disease to longer periods of viral RNA detection by RT-PCR, whereas others have not replicated these findings. [1] [2] [3] The average time from first positive to first negative RT-PCR results has been described as less than 4 weeks, although the actual infectious period is postulated to be shorter. [1] [2] [3] [4] [5] Some reports describe individuals with viral RNA detection up to 63 days, or longer in rare cases of immunocompromised individuals, undefined clinical course, or recrudescence. [6] [7] [8] [9] [10] [11] [12] Namibia's first reported cases of the 2019 coronavirus disease (COVID-19) were announced on March 14, 2020. A married couple, a 34-year-old man (Patient 1) and a 24-year-old woman (Patient 2), both living in Spain, had traveled to Namibia by air. Patient 1 developed symptoms of fever, dry cough, and fatigue while in transit on March 10 and sought medical evaluation within hours of arriving in Namibia. Patient 2 had no symptoms. Both were tested by nasopharyngeal (NP) and oropharyngeal (OP) swabs on March 11 and were positive for SARS-CoV-2 by RT-PCR. After an initial retesting by both NP and OP swabs, all subsequent tests were by NP swab only. Neither person had preexisting medical conditions to increase risk for severe illness from COVID-19.

Both patients were kept in an isolation facility for patients with mild cases of COVID-19. The patients had contact only with health care providers in appropriate personal protective equipment. Patent 1's symptoms fully resolved in 10 days after onset, and Patient 2 did not develop any symptoms. However, RT-PCR testing continued to show presence of viral RNA after more than 2 months of testing (Table 1) . Based on availability, 2 assays were used in Namibia over the course of testing done in the country (Table 1) Yat-Sen University, Guangzhou, China, http://en.daangene.com/). Both of these assays have been independently evaluated on the Roche 480 LightCycler PCR platform using 50 positives and 100 negatives, and the sensitivity and specificity were found to be as follows: TIB gene target E sensitivity 100% (95% CI: 93, 100) and specificity 100% (95% CI: 96, 100), DA AN gene target ORF1 sensitivity 100% (95% CI: 93, 100) and specificity 96% (95% CI: 90, 98), and DA AN gene target N sensitivity 100% (95% CI: 93, 100) and specificity 98% (95% CI: 93, 99) (https:// www.finddx.org/covid-19/sarscov2-eval-molecular/molecular-eval-results/). All testing included internal controls, as well as extraction, positive, and negative controls to ensure testing quality and valid results. Cycle threshold values were not consistently reported, and a viral culture was not able to be performed. Additional published data regarding time to viral clearance and detection by RT-PCR will be valuable for public health officials and clinicians in their decision-making regarding patient isolation. More data are needed on the correlation between repeatedly testing positive for SARS-CoV-2 by RT-PCR and infectivity, viral load as a possible determinant, and the role of antigen tests or other accessible measures that can determine the presence of a viable virus. 13, 14 In settings where re-introduction of transmission to a community is of great concern, but isolation facility space is limited, a better understanding of infectivity duration would inform policies for use of limited resources and for reducing unnecessary burden on those infected.

Conflict(s) of Interest. The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this paper. 2 T-B Kandetu et al.

Factors associated with duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study

Factors associated with prolonged viral RNA shedding in patients with COVID-19

Comparison of clinical characteristics of patients with asymptomatic vs symptomatic coronavirus disease 2019 in Wuhan, China

Persistent detection of SARS-CoV-2 RNA in patients and healthcare workers with COVID-19

Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients

Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients

Case report: viral shedding for 60 days in a woman with COVID-19

Prolonged persistence of SARS-CoV-2 RNA in body fluids

Prolonged virus shedding even after seroconversion in a patient with COVID-19

Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised cancer patient

Prolonged SARS-CoV-2 RNA shedding: not a rare phenomenon

Persistent viral RNA positivity during recovery period of a patient with SARS-CoV-2 infection

Predicting infectious SARS-CoV-2 from diagnostic samples

Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards